AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NovaBay Pharmaceuticals, Inc.

$0.89 -$0.35 (-27.97%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$0.86
Day Range
$0.87$0.92
Year Range
$0.83$2.13
Market Cap
45.06M
AVG Volume
835.75K
Trailing/Forward PE
0.06/-
PEG ratio
0
Dividend Yield
447.83%
Next Earnings Date
2026-11-05
Primary Exchange
New York Stock Exchange ArcaUS
Revenue (USD) · TTM
02.5M5M7.5M10M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q24.67M
26 Q12.46M
25 Q40
25 Q3521K
25 Q20
25 Q10
24 Q40
24 Q32.1M
24 Q24.58M
24 Q18.12M
Net Income (USD) · TTM
-200M0200M400M600M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2483.44M
26 Q1522.59M
25 Q4-33.34M
25 Q3-7.96M
25 Q2-7.88M
25 Q1-7.54M
24 Q4-7.22M
24 Q3-7.73M
24 Q2-7.87M
24 Q1-8.01M
Operating Income (USD) · TTM
-10M-7.5M-5M-2.5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-6.59M
26 Q1-5.27M
25 Q4-7.58M
25 Q3-7.53M
25 Q2-8.06M
25 Q1-7.79M
24 Q4-7.38M
24 Q3-6.62M
24 Q2-5.61M
24 Q1-5.05M
EBITDA (USD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-6.54M
26 Q1-5.18M
25 Q4-7.45M
25 Q3-7.34M
25 Q2-7.82M
25 Q1-7.49M
24 Q4-7.04M
24 Q3-6.25M
24 Q2-5.32M
24 Q1-4.83M
Cash Flows (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-11.88M
26 Q1-8.91M
25 Q4-8.43M
25 Q3-7.71M
25 Q2-8.32M
25 Q1-6.84M
24 Q4-7.5M
24 Q3-6.37M
24 Q2-4.57M
24 Q1-5.06M
EPS (USD) · TTM
-600-400-200024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-3.66
26 Q1-3.99
25 Q4-10.65
25 Q3-7.32
25 Q2-15.82
25 Q1-21.03
24 Q4-167.45
24 Q3-304.49
24 Q2-345.37
24 Q1-584.17
Expenses (USD) · TTM
-5M05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q211.21M
26 Q17.65M
25 Q47.45M
25 Q37.42M
25 Q27.83M
25 Q17.51M
24 Q47.08M
24 Q37.46M
24 Q28.21M
24 Q19.46M
Shares Outstanding (USD) · TTM
-2M-1M01M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2537K
26 Q1-1.28M
25 Q4187K
25 Q30
25 Q20
25 Q11.81M
24 Q40
24 Q30
24 Q20
24 Q10
Dividends (USD)
0246Sep 25
SDEV Dividends (USD) by quarter
PeriodDividends (USD)
Sep 254
PE Ratio
0.040.050.060.07med 0.06Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV PE Ratio by quarter
PeriodPE Ratio
Sep 260.06
Sep 260.06
Aug 260.05
Aug 260.06
Aug 260.05
Aug 260.05
Jul 260.06
Jul 260.05
Jul 260.06
Jul 260.07
Jul 260.07
Jun 260.06
Jun 260.06
Jun 260.05
Jun 260.06
Free Cash Flow Yield
-125%-100%-75%-50%-25%med -42.85%Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
SDEV Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-42.85%
Sep 26-43.01%
Aug 26-36.65%
Aug 26-30.04%
Aug 26-33.25%
Aug 26-33.25%
Jul 26-29.78%
Jul 26-31.14%
Jul 26-27.4%
Jul 26-25.75%
Jul 26-25.18%
Jun 26-30.86%
Jun 26-28.07%
Jun 26-33.91%
Jun 26-30.58%
May 26-114.05%
May 26-102.73%
May 26-88.32%
May 26-88.86%
May 26-110.57%
Apr 26-108.91%
Apr 26-94.06%
Apr 26-90.53%
Apr 26-74.28%
Mar 26-96.56%
Mar 26-124.87%
Mar 26-119.71%
Price to Sales
57.51012.515med 11.72Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV Price to Sales by quarter
PeriodPrice to Sales
Sep 265.94
Sep 265.92
Aug 269.87
Aug 2612.04
Aug 2610.88
Aug 2610.88
Jul 2612.15
Jul 2611.62
Jul 2613.2
Jul 2614.05
Jul 2614.36
Jun 2611.72
Jun 2612.89
Jun 2610.67
Jun 2611.83
Price to Book
0.160.180.20.220.240.26med 0.21Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV Price to Book by quarter
PeriodPrice to Book
Sep 260.22
Sep 260.22
Aug 260.18
Aug 260.21
Aug 260.19
Aug 260.19
Jul 260.22
Jul 260.21
Jul 260.23
Jul 260.25
Jul 260.25
Jun 260.21
Jun 260.23
Jun 260.19
Jun 260.21
NovaBay Pharmaceuticals, Inc.
SDEV
Stockpicker

Video analysis: SDEV

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SDEV

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average   – What’s Next?

defenseworld.net · 15 Aug 2026

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Stablecoin Development Corporation (NYSEAMERICAN:SDEV - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.93 and traded as low as $1.01. Stablecoin Development shares last traded at $1.03, with a volume of 75,165 shares. Stablecoin Development

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

globenewswire.com · 3 Aug 2026

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

globenewswire.com · 31 Jul 2026

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026  SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant liabilities from its balance sheet WEST PALM BEACH, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- Stablecoin Development Corporation (NYSE American: SDEV) (the “Company” or “SDEV”), an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems and providing public market access to the stablecoin economy, yesterday reported financial results for the second quarter and first half ended June 30, 2026.

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

globenewswire.com · 17 Jun 2026

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly NovaBay Pharmaceuticals, Inc.) who held their shares prior to August 19, 2025.

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.